Our results clearly showed that CSF p-tau181 was mildly but significantly elevated in patients with high amyloid pathological scores, even in those with limited tau pathology to the transentorhinal region (Braak NFT stage 0–II) at autopsy. The gene discussed is MAPT; the disease is amyloidosis.